Parallax Volatility Advisers
NTLA icon

Parallax Volatility Advisers’s Intellia Therapeutics NTLA Stock Holding History

Parallax Volatility Advisers’s Portfolio NTLA Stock Details NTLA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q4 		– Sell
-100
Closed -$13K – 3303
2021
Q3 		$13K Sell
100
-63,800
-100% -$9.66M ﹤0.01% 2786
2021
Q2 		$10.3M Buy
+63,900
New +$4.98M 0.01% 875

Other funds holding NTLA

AIM
ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
RP
Regeneron Pharmaceuticals Tarrytown, New York $177M AUM 9.82% 1-Year Est. Return
NAMA
Nikko Asset Management Americas New York $7.75B AUM 33.73% 1-Year Est. Return
Sumitomo Mitsui Trust Group
Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $175B AUM 40.63% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Parallax Volatility Advisers's NTLA Position: Q4 2024 in Review

Parallax Volatility Advisers sold out of Intellia Therapeutics (NTLA) in Q4 2024, closing a stake of 35,994 shares — an estimated $740K sold.

Parallax Volatility Advisers first reported a position in NTLA in Q4 2017 and held it in 10 quarters. The position peaked at $4.66M in Q2 2021. 295 funds tracked by Wall St. Rank hold NTLA as of Q4 2024.

  • Parallax Volatility Advisers reported no remaining Intellia Therapeutics position as of Q4 2024 after selling out during the quarter.
  • Parallax Volatility Advisers sold 35,994 Intellia Therapeutics shares in Q4 2024, an estimated $740K.
  • Parallax Volatility Advisers first reported a position in Intellia Therapeutics in Q4 2017 and held it in 10 quarters.
  • Parallax Volatility Advisers's Intellia Therapeutics position peaked at $4.66M in Q2 2021.
  • 295 funds tracked by Wall St. Rank held Intellia Therapeutics as of Q4 2024.

Based on Parallax Volatility Advisers's 13F filing for Q4 2024, filed 14 Feb 2025.